Our team boasts a wealth of experience, from academia to long-established CDMO experts. Our team is on hand to support you throughout your journey to therapy, we understand your needs and are driven to help you bring your products to patients. Learn more about our experience, what brings us to Genezen and what motivates us every day.
Founded in 2014 by current Chairman Bill Vincent, our history is packed with innovation and ambition. Following investment by Ampersand Capital Partners’ in 2021, Genezen is catapulted forward built on a foundation of expansive knowledge in lentiviral and retroviral vector.
We collaborate with our clients to connect good science with better cures. With superior service and technical expertise, we develop and manufacture cell and gene therapy products of the highest quality.